Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25978877 | 0.84 | — | — | |
| SCHEMBL15087751 | 0.81 | — | — | |
| SCHEMBL15182435 | 0.76 | CTSA (0.30) | ACHE | |
| SCHEMBL8650070 | 0.75 | TSHR (0.50) | ACHETSHRPPARDTP53TDP1 | |
| SCHEMBL11861492 | 0.71 | PPARD (0.43) | ACHETSHRPPARDTP53TDP1 | |
| SCHEMBL3097323 | 0.70 | TSHR (0.40) | ACHETSHRPPARDALOX15TP53 | |
| SCHEMBL16562635 | 0.70 | — | — | |
| SCHEMBL10597368 | 0.69 | FDPS (0.32) | ALOX15 | |
| SCHEMBL10389565 | 0.66 | TSHR (0.40) | TSHRPPARDALOX15TP53TDP1 | |
| SCHEMBL23652502 | 0.66 | ACHE (0.35) | ACHETSHRPPARDALOX15TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218244-A1 | ANTISENSE NUCLEIC ACIDS | NIPPON SHINYAKU CO., LTD. (JP) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218244-A1 | ANTISENSE NUCLEIC ACIDS | UTRN, RBM17, UPF1 | ACHE 4181/4885TSHR 3246/4885PPARD 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.